A rare disease pharmaceutical company acquiring, developing and commercializing therapeutics, specializing in gastroenterology.
Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases.Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people.We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases.We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI motility disorders.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 1, 2019 | Series B | $2.90M | 1 | — | — | Detail |
Nov 1, 2016 | Series B | $24M | 1 | — | — | Detail |
Jan 1, 2013 | Series A | $23.10M | 1 | — | — | Detail |
Mar 1, 2007 | Seed | $6.80M | 1 | Ionis Pharmaceuticals | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Ionis Pharmaceuticals | Yes | Seed |
EndoLogic USA | — | Series B |
Fullbrook Thorpe Investments | — | Series B |